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• Detailed safety data from the SOLO1 trial of maintenance olaparib in newly diagnosed, advanced BRCA-mutated ovarian cancer.
• Maintenance olaparib had a predictable tolerability profile with no new safety signals identified.
• Adverse events usually occurred early, were largely manageable and led to discontinuation in a minority of patients.
• Risk of MDS/AML with maintenance olaparib in the newly diagnosed setting remained <1.5% with long-term follow-up of 5 years.
• The majority of patients were able to remain on the recommended starting dose of olaparib 300 mg twice daily.⁎ Corresponding author at: University of Milan-Bicocca
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OlaparibObjectives. In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial
progression-free survival benefit in patients with newly diagnosed, advanced ovarian cancer and a BRCA muta-
tion who were in response after platinum-based chemotherapy. We analyzed the timing, duration and grade of
the most common hematologic and non-hematologic adverse events in SOLO1.
Methods. Eligible patientswere randomized to olaparib tablets 300mg twice daily (N=260) or placebo (N=
131), with a 2-year treatment cap in most patients. Safety outcomes were analyzed in detail in randomized pa-
tients who received at least one dose of study drug (olaparib, n = 260; placebo, n = 130).and IEO European Institute of Oncology IRCCS, Via Ripamonti 435, Milan 20141, Italy.
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Tolerability
Safety
Newly diagnosedResults.Median time to first onset of the most common hematologic (anemia, neutropenia, thrombocytope-
nia) and non-hematologic (nausea, fatigue/asthenia, vomiting) adverse events was <3 months in olaparib-
treated patients. The first event of anemia, neutropenia, thrombocytopenia, nausea and vomiting lasted amedian
of <2months and the first event of fatigue/asthenia lasted a median of 3.48months in the olaparib group. These
adverse events were manageable with supportive treatment and/or olaparib dosemodification inmost patients,
with few patients requiring discontinuation of olaparib. Of 162 patients still receiving olaparib atmonth 24, 64.2%
were receiving the recommended starting dose of olaparib 300 mg twice daily.
Conclusions. Maintenance olaparib had a predictable and manageable adverse event profile in the newly di-
agnosed setting with no new safety signals identified. Adverse events usually occurred early, were largely man-
ageable and led to discontinuation in a minority of patients.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
In women with newly diagnosed, advanced ovarian cancer who are
in response to first-line platinum-based chemotherapy, maintenance
therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor
olaparib is approved in theUSA, the EU, China, Japanand other countries
worldwide for women with a BRCA1 and/or BRCA2 mutation (BRCAm)
[1–4] and maintenance olaparib plus bevacizumab is approved in the
USA, the EU and Japan for womenwho test positive for homologous re-
combination deficiency (BRCAm and/or genomic instability) [1,2,5].
Given that following cytoreductive surgery and platinum-based che-
motherapy, patients with newly diagnosed, advanced ovarian cancer
will receive maintenance olaparib for a planned 2 years in the setting of
no or minimal disease, it is important to establish that olaparib does not
add a significant safety or toxicity burden. Adverse events (AEs) should
be manageable over time and not lead to treatment discontinuation.
In the phase III SOLO1 trial (NCT01844986; GOG-3004), mainte-
nance olaparib provided a substantial progression-free survival (PFS)
benefit in women with newly diagnosed, advanced ovarian cancer and
a BRCAm who were in response after platinum-based chemotherapy
[6]. In the primary analysis, the risk of disease progression or death
was significantly reduced by 70% with olaparib versus placebo (hazard
ratio 0.30; 95% CI 0.23–0.41; primary endpoint) [6]. With longer-term
follow-up, 48.3% of olaparib patients versus 20.5% of placebo patients
were progression free at 5 years (Kaplan-Meier estimates) [7]. The
safety profile of maintenance olaparib in the newly diagnosed setting
[6] was consistent with that previously reported in the relapsed disease
setting [8,9].
The current analysis provides further information about the safety
and tolerability of maintenance olaparib in women with newly diag-
nosed, advanced ovarian cancer and a BRCAm in the SOLO1 trial,
with a focus on the most commonly reported hematologic and non-
hematologic AEs.
2. Methods
2.1. Study design and patients
The design of the randomized, double-blind, multicenter, phase III
SOLO1 study has been reported previously [6]. In brief, eligible patients
had newly diagnosed, histologically confirmed, International Federation
of Gynecology and Obstetrics (FIGO) stage III–IV, high-grade serous or
endometrioid ovarian cancer, primary peritoneal cancer and/or
fallopian tube cancer and a BRCAm. Patients with stage III disease had
an upfront or interval attempt at optimal cytoreductive surgery and pa-
tients with stage IV disease had a biopsy and/or upfront or interval
cytoreductive surgery. Patients had received first-line platinum-based
chemotherapy andwere in clinical complete response (CR) or partial re-
sponse (PR) [6]. Any persistent toxicities associated with prior chemo-
therapy (excluding alopecia) were required to have improved to
grade ≤1. Patients were required to have a baseline hemoglobin level
of ≥10.0 g/dL (with no blood transfusion in the past 28 days), an2
absolute neutrophil count of ≥1.5 × 109/L, and a platelet count of
≥100 × 109/L. Full eligibility criteria are provided in the Supplementary
Appendix.
The trial was performed in accordance with the Declaration of Hel-
sinki, Good Clinical Practice Guidelines and the AstraZeneca policy of
bioethics, under the auspices of an Independent Data Monitoring Com-
mittee. AstraZenecawas responsible for overseeing the collection, anal-
ysis and interpretation of the data. All patients provided written
informed consent.
2.2. Random assignment and procedures
Within 8 weeks of completing platinum-based chemotherapy, pa-
tients were randomized in a 2:1 ratio to olaparib tablets 300 mg twice
daily or matching placebo using an interactive voice and web response
system. Randomization used a block designwith stratification according
to the response to platinum-based chemotherapy (clinical CR or PR).
Study treatment continued until investigator-assessed objective ra-
diologic disease progression (modified Response Evaluation Criteria in
Solid Tumors [RECIST] version 1.1 criteria), stopped at 2 years in pa-
tients who achieved CR or with no evidence of disease, or could con-
tinue beyond 2 years in patients with ongoing PR.
AEsweremonitored during, and for 30 days after discontinuation of,
study treatment and were graded using National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE), version 4.0. All
ongoing AEs at the time of study treatment discontinuation and any
new AEs identified during the 30-day safety follow-up period were
followed to resolution unless they were considered unlikely to resolve
or the patient was lost to follow-up. Follow-up formyelodysplastic syn-
dromes (MDS)/acutemyeloid leukemia (AML) and new primarymalig-
nancies was actively continued alongside survival follow-up.
Supportive treatment for AEs was administered according to local
practice guidelines, with toxicity also managed by dose modification
or discontinuation (Supplementary Appendix).
2.3. Outcomes
The primary efficacy endpoint in SOLO1 (investigator-assessed PFS
according to modified RECIST version 1.1 criteria) has been reported
previously [6].
The safety and tolerability of maintenance olaparib was also
assessed. The incidence and prevalence of the most common hemato-
logic and non-hematologic AEs were analyzed. Grouped-term data are
provided for fatigue/asthenia and the hematologic AEs (Supplementary
Appendix). The time to onset, duration andmanagement of the first ep-
isode of these AEs were analyzed, as well as the management and out-
come of all episodes of these events.
2.4. Statistical analysis
As previously reported [6], SOLO1was powered to detect differences
in PFS.
N. Colombo, K. Moore, G. Scambia et al. Gynecologic Oncology xxx (xxxx) xxxSafety data were summarized in the safety analysis set (i.e. all ran-
domized patients who received at least one dose of study treatment)
and were summarized descriptively with no formal statistical analyses
performed.
3. Results
Between September 3, 2013 and March 6, 2015, 391 patients were
randomized, with 260 assigned to olaparib and 131 to placebo
(Fig. S1). The safety analysis set comprised 260 olaparib and 130 pla-
cebo patients (one patient randomized to placebo withdrew before re-
ceiving study treatment). The date of data cut-off (DCO) for the
primary analysis was May 17, 2018.
As previously reported, baseline characteristics were well balanced
between treatment groups (Table 1) [6]. Nausea, asthenia, neutropenia
and thrombocytopenia (all grades) were reported in few patients at
baseline (Table 1). At baseline, fatigue was reported in 16.5% of olaparib
patients and 19.8% of placebo patients, and anemia was reported in






Response after platinum-based chemotherapy, n (%)
Clinical complete responsea 213 (81.9) 107 (81.7)
Clinical partial responseb 47 (18.1) 24 (18.3)
ECOG performance status, n (%)
0 200 (76.9) 105 (80.2)
1 60 (23.1) 25 (19.1)
Missing 0 1 (0.8)
Primary tumor location, n (%)
Ovary 220 (84.6) 113 (86.3)
Fallopian tubes 22 (8.5) 11 (8.4)
Primary peritoneal 15 (5.8) 7 (5.3)
Otherc 3 (1.2) 0
FIGO stage, n (%)
III 220 (84.6) 105 (80.2)
IV 40 (15.4) 26 (19.8)
Histology, n (%)
Serous 246 (94.6) 130 (99.2)
Endometrioid 9 (3.5) 0
Mixed serous/endometrioid 5 (1.9) 1 (0.8)
BRCA mutation,d n (%)
BRCA1 191 (73.5) 91 (69.5)
BRCA2 66 (25.4) 40 (30.5)
Both BRCA1 and BRCA2 3 (1.2) 0
Adverse events at baseline,e n (%)
Nausea 15 (5.8) 9 (6.9)
Fatigue 43 (16.5) 26 (19.8)
Asthenia 12 (4.6) 4 (3.1)
Vomiting 0 1 (0.8)
Anemiaf 50 (19.2) 14 (10.7)
Neutropeniaf 2 (0.8) 4 (3.1)
Thrombocytopeniaf 1 (0.4) 0
ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology
and Obstetrics; MedDRA, Medical Dictionary for Regulatory Activities; RECIST, Response
Evaluation Criteria in Solid Tumors.
a Clinical complete response was defined as no evidence of disease on the post-treat-
ment scan (according to modified RECIST, version 1.1) after chemotherapy and a normal
CA-125 level.
b Partial response was defined as a ≥30% reduction in tumor volume from the start to
the end of chemotherapy or no evidence of disease on the post-treatment scan, but a CA-
125 level above the upper limit of normal.
c Other tumor locations included a combination of the ovary, fallopian tube, perito-
neum, and omentum (n = 1), a combination of the ovary and peritoneum (n= 1), and a
combination of the ovary and fallopian tube (n = 1).
d BRCA mutation status was determined centrally or locally.
e Adverse events recorded by investigators on the electronic case report form at base-
line (MedDRA preferred term).
f Grade was not recorded, although at study entry, patients were required to have he-
moglobin of ≥10.0 g/dL with no blood transfusion in the past 28 days, an absolute neutro-
phil count of ≥1.5× 109/L, and a platelet count of ≥100×109/L (Supplementary Appendix).
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Themedian (interquartile range [IQR]) duration of follow-up for the
primary efficacy analysis was 40.7 months (34.9–42.9) for olaparib and
41.2 months (32.2–41.6) for placebo and the median (IQR) total dura-
tion of treatment was 24.6 months (11.2–24.9) for olaparib (consistent
with the 2-year treatment cap) and 13.9 months (8.0–24.8) for placebo
(consistent with the median PFS of 13.8 months in the placebo group).
Treatment continued for at least 2 years in 57.3% of olaparib patients
(47.3% completed 2 years' treatment and10.0% continued treatment be-
yond 2 years) and 29.2% of placebo patients (26.9% completed 2 years'
treatment and 2.3% continued treatment beyond 2 years).
At the primary DCO, 47.3% of patients in the olaparib group and
26.9% of patients in the placebo group had completed 2 years ofmainte-
nance therapy per protocol, 47.7% and 72.3%, respectively, had
discontinued maintenance therapy for a reason other than the
protocol-defined 2-year stopping rule and 5.0% and 0.8%, respectively,
were still receiving maintenance therapy (Fig. S1). Reasons for discon-
tinuation other than the 2-year stopping rule included disease progres-
sion (19.6% of olaparib patients vs 60.0% of placebo patients), adverse
events (11.5% vs 2.3%), patient decision (8.5% vs 1.5%) and other reasons
(8.1% vs 8.5%).
The most common AEs (all grades) were nausea, fatigue/asthenia,
vomiting, anemia and diarrhea (Supplementary Table S1). AEs were
predominantly grade 1–2, apart from anemia,whichwas themost com-
mon grade ≥3 AE (Supplementary Table S1).
Serious AEs occurred in 20.8% of olaparib patients and 12.3% of pla-
cebo patients; anemia was the most common serious AE (6.9% vs 0%)
(Supplementary Table S2).
No AEs that occurred during administration of olaparib or placebo or
up to 30 days after discontinuation of olaparib or placebo resulted in
death.
The most common hematologic AEs were anemia, neutropenia and
thrombocytopenia (Supplementary Table S1), with a median time to
first onset (any grade) of 1.94, 1.77 and 2.83 months, respectively, for
olaparib (Fig. 1A). For olaparib, resolution of the first event of anemia,
neutropenia and thrombocytopenia occurred in the vast majority of pa-
tients experiencing these AEs (Fig. 1B), with the first event lasting ame-
dian of 1.87, 0.76 and 0.95months, respectively (Fig. 1C). Olaparib dose
reduction occurred in 43.6%, 15.8% and 16.0% of patients with resolution
of anemia, neutropenia and thrombocytopenia, respectively (Supple-
mentary Table S3).
For olaparib, the prevalence of anemia peaked at 6 months, with a
reduction in the prevalence of grade 2 or worse anemia over time
(Fig. 2A), and the prevalence of neutropenia (Fig. 2C) and thrombocyto-
penia (Fig. 2E) remained low; thrombocytopenia was predominantly
grade 1 and neutropenia was predominantly grade 2 or higher. In the
placebo group, the prevalence of hematologic AEs over time was low
(Fig. 2B, D and F).
Overall, the median number of events per patient receiving olaparib
was 1.0 for anemia and neutropenia and 2.0 for thrombocytopenia
(Table 2). These AEs were usually managed with supportive treatment
or dose modification, with few patients discontinuing olaparib
(Table 2). At least one blood transfusion was administered to 60.4% of
patients with anemia in the olaparib group and 23.1% of patients with
anemia in the placebo group (Supplementary Appendix).
Most of the patients in the olaparib groupwith anemia, neutropenia
or thrombocytopenia experienced recovery or resolution of the AE
(Table 2).
Nausea, fatigue/asthenia and vomiting, the most common non-
hematologic AEs in SOLO1, were predominantly grade 1 or 2 (Supple-
mentary Table S1). For olaparib, themedian time tofirst onset of nausea,
fatigue/asthenia and vomiting of any grade was 0.13, 0.72 and 1.46
months, respectively (Fig. 1A). Resolution of the first event of nausea
or vomiting occurred in >90% of olaparib patients experiencing these
AEs (Fig. 1B), with the first event lasting a median of 1.41 and 0.07
months, respectively (Fig. 1C). The first event of fatigue/asthenia re-
solved in 76.4% of olaparib patients (Fig. 1B), with the first occurrence
Fig. 1. First occurrence of the most commonly reported hematologic and non-hematologic adverse events. Panel A shows the median time to first event. Circles represent medians, bars
represent ranges. Panel B shows the proportion of patients with a first event with a resolution date; resolution was determined by the investigator. Percentages were calculated from the
number of patients with a first event (shownbelow the bars) and take into account the date of data cut-off and the events that had a resolution date. Panel C shows themedian duration of
the first event. Adverse events with no end date were censored at the end of the safety follow-up or at data cut-off, as applicable.
N. Colombo, K. Moore, G. Scambia et al. Gynecologic Oncology xxx (xxxx) xxxlasting a median of 3.48 months (Fig. 1C). Few olaparib patients re-
quired dose reduction to manage the first event of nausea, fatigue/as-
thenia or vomiting (Supplementary Table S3).
Nausea was themost common AE in the first month of maintenance
olaparib; however, its prevalence and severity decreased rapidly
(Fig. 2G). Although the overall prevalence of fatigue/asthenia appeared
stable over time in the olaparib group, grade 2 orworse fatigue/asthenia
decreased over time (Fig. 2I). The prevalence of vomiting, which was
predominantly grade 1, remained lowover time (Fig. 2K). In the placebo
group, the prevalence of nausea (Fig. 2H) and vomiting (Fig. 2J) over
timewas low, with an apparent increase in the prevalence of fatigue/as-
thenia at 14 months (Fig. 2L).
The median number of events per patient in the olaparib group was
1.0 for nausea, fatigue/asthenia and vomiting (Table 2). These AEs were
usually managed with supportive treatment or dose modification, with
few patients discontinuing olaparib (Table 2). Propulsives (most com-
monly metoclopramide) were administered to 32.7% of olaparib pa-
tients versus 13.7% of placebo patients and serotonin 5-HT3 receptor
antagonists were administered to 23.8% versus 16.0%, respectively (as
reported on electronic case report forms) (Supplementary Appendix).
Most of the patients in the olaparib group with nausea, fatigue/as-
thenia or vomiting experienced recovery or resolution of the AE
(Table 2).
Clinical chemistry results did not identify any new safety concerns.
No clinically significant changes from baseline in clinical chemistry pa-
rameters (including albumin, alanine aminotransferase, aspartate4
aminotransferase, alkaline phosphatase, gamma glutamyltransferase
and bilirubin) occurred in the olaparib or placebo groups. An increased
blood creatinine level was reported as an AE in 8.1% of patients in the
olaparib group and in 1.5% of patients in the placebo group; all increases
in blood creatinine were grade 1 and none resulted in study drug
discontinuation.
Overall, AEs led to dose interruption in 51.9% of olaparib patients
versus 16.9% of placebo patients, dose reduction in 28.5% versus 3.1%,
respectively, and study drug discontinuation in 11.5% versus 2.3%, re-
spectively. The median (IQR) duration of dose interruption because of
AEs was 15.5 days (7–36) in the olaparib group and 13 days (7–17) in
the placebo group. Of the 162 patients still receiving olaparib at
month 24, 104 (64.2%) were receiving the recommended starting dose
of olaparib 300 mg twice daily (Fig. 3). For olaparib, the most common
AEs leading to dose reduction were anemia, fatigue, nausea and neutro-
penia (Supplementary Table S5). The most common AEs leading to
study drug discontinuation were nausea (2.3% of olaparib patients vs
0.8% of placebo patients), anemia (2.3% vs 0%) and fatigue/asthenia
(2.3% vs 0.8%).
MDS/AML, new primary malignancies and pneumonitis/interstitial
lung disease (ILD) are AEs of interest for olaparib. AML was reported
in three (1.2%) olaparib patients (Table 3), with all three cases resulting
in death; no cases of MDS/AML were reported for placebo. Because
death occurred >30 days after discontinuation of olaparib, these AML
cases were not classified as AEs resulting in death. Following the pri-
mary analysis DCO, no new cases of MDS/AML were reported in either
Fig. 2. Prevalence by month and grade for the most common adverse events. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0. The number of patients at risk is the number of patients at each time point who were receiving olaparib or placebo or who were in safety follow-up to 30
days after the end of treatment. AE, adverse event.
N. Colombo, K. Moore, G. Scambia et al. Gynecologic Oncology xxx (xxxx) xxxtreatment group during longer-term follow-up (total median [IQR] du-
ration of follow-up of 58.1 months [33.8–64.1] for olaparib and 59.6
months [30.8–63.5] for placebo) (DCO March 5, 2020).
New primary malignancies (excluding MDS/AML) had been re-
ported in a total of seven (2.7%) olaparib patients and five (3.8%) pla-
cebo patients at the March 5, 2020 DCO (Supplementary Appendix).
Pneumonitis/ILD occurred in five (1.9%) of 260 patients in the
olaparib group and no patients in the placebo group (Supplementary
Appendix).
4. Discussion
In SOLO1, maintenance olaparib was associated with an unprece-
dented PFS benefit in patients with newly diagnosed advanced ovarian
cancer and a BRCAm [6], and represents a new standard of care in this
population [10]. Maintenance therapy with olaparib was capped at 2
years, meaning somepatients were able to live progression-free for sev-
eral years without treatment and its associated AEs [6,7]. To our knowl-
edge, we report here the first detailed safety data for PARP inhibitor
maintenance therapy in the newly diagnosed setting.5
No new safety signals were identified and AEs were mostly mild to
moderate, with anemia being the most common grade ≥3 AE. Anemia,
neutropenia, thrombocytopenia, nausea, fatigue/asthenia and vomiting
usually occurred early, although the peak in anemia prevalence at 6
months for olaparib is slightly later than previously reported in the re-
lapsed disease setting [11]. The prevalence of fatigue/asthenia remained
relatively constant throughout the olaparib treatment period; 29% of
patients with fatigue/asthenia did not recover and other patients may
have experienced recurrent episodes. The apparent increase in fa-
tigue/asthenia with placebo at 14monthsmay reflect the impact of dis-
ease relapse (median PFS of 13.8 months in the placebo group versus
56.0 months in the olaparib group) [7]. Anemia, neutropenia, thrombo-
cytopenia, nausea and vomiting were usually manageable with sup-
portive therapy and/or dose modification.
Strict monitoring for anemia is suggested at the beginning of
olaparib maintenance therapy. Complete blood counts should be per-
formed monthly for the first 12 months, with periodic monitoring rec-
ommended thereafter [12]. Hematologic AEs should be managed with
olaparib dose modification and, where appropriate, blood transfusion
[12,13]. It may also be prudent to check folate levels in patients with
Fig. 2 (continued).
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in a small number of patients receiving olaparib in the relapsed disease
setting; administering folate supplements ameliorated the requirement
for transfusion and olaparib dose modification in one patient [14].
Interruption ofmaintenance olaparib is recommended for severe he-
matologic toxicity or blood transfusion dependence [12]; blood counts
should be monitored weekly until recovery. Bone marrow and/or
blood cytogenetic analyses are recommended in patients with persis-
tently abnormal blood parameters 4weeks after interruption of olaparib
[12].
Nausea and vomiting are usually manageable with antinausea/anti-
emetic therapy and/or olaparib dosemodification [12,15]. Although an-
tinausea prophylaxis is not recommended when maintenance olaparib
is first started, it should be used in patients who subsequently experi-
ence nausea. In most cases, antinausea prophylaxis can be stopped
after the first 2–3 months of therapy.
Supportive care (e.g. strategies to conserve energy) and dose modi-
fication can be used to manage fatigue/asthenia [12,15]. Although the
prevalence of fatigue/asthenia appeared stable over time with olaparib
in SOLO1, it was of predominantly grade 1 severity and few patients re-
quired dose reduction or discontinuation. Other possible causes of fa-
tigue (e.g. anemia or depression) should be excluded in patients with
ongoing fatigue [12,15].6
Few SOLO1 patients required discontinuation of maintenance
olaparib because of anemia, neutropenia, thrombocytopenia, nausea, fa-
tigue/asthenia or vomiting.
The increase in blood creatinine level seen in some patients receiving
maintenance olaparib might be explained by inhibition of renal trans-
porters such as OCT2, MATE1 andMATE2K by olaparib leading to inhibi-
tion of tubular secretion of creatinine, as increases in blood creatinine
levels were found to be reversible after discontinuation of olaparib [16].
During the 24-month treatment period in SOLO1, themajority of pa-
tients (64%) still receiving treatment remained on the olaparib starting
dose without requiring dose reduction, with 17% receiving a reduced
olaparib dose of 250 mg twice daily.
In terms of AEs of special interest, it is reassuring that no new cases
of MDS/AML were reported between the primary analysis DCO and the
DCO at March 5, 2020, and the incidence of new primary malignancies
remained balanced between the treatment groups after approximately
5 years of follow-up.MDS/AML also occurs in patients with ovarian can-
cer who have not been exposed to PARP inhibitors [17], with a back-
ground risk of MDS/AML associated with use of select DNA-damaging
therapies (including platinum-based agents) in earlier lines of chemo-
therapy [17].
Limited data are available concerning the risk of pneumonitis/ILD in
patients receiving PARP inhibitor maintenance therapy. Five cases of
Table 2
Management and outcome of the most commonly reported hematologic and non-hematologic adverse events.













Patients with event (all grades), n (%) 101 (38.8) 13 (10.0) 60 (23.1) 15 (11.5) 29 (11.2) 5 (3.8)
Median (range) number of adverse events per patient 1.00 (1–9) 1.00 (1–5) 1.00 (1–7) 1.00 (1–8) 2.00 (1–9) 1.00 (1–3)
Management, n (%)
Supportive treatment 72 (27.7) 4 (3.1) 11 (4.2) 2 (1.5) 2 (0.8) 1 (0.8)
Dose interruption 58 (22.3) 1 (0.8) 30 (11.5) 5 (3.8) 6 (2.3) 0
Dose reduction 44 (16.9) 1 (0.8) 10 (3.8) 1 (0.8) 4 (1.5) 0
Discontinuation 6 (2.3) 0 1 (0.4) 0 1 (0.4) 0
Outcome, n (%)b
Recovered/resolved 84 (83.2) 11 (84.6) 53 (88.3) 14 (93.3) 21 (72.4) 4 (80.0)
Recovered/resolved with sequelae 2 (2.0) 0 0 0 2 (6.9) 0
Recovering/resolving 5 (5.0) 0 1 (1.7) 0 0 0
Not recovered/resolved 10 (9.9) 2 (15.4) 6 (10.0) 1 (6.7) 6 (20.7) 1 (20.0)
Patients with grade ≥3 events, n (%) 56 (21.5) 2 (1.5) 22 (8.5) 6 (4.6) 2 (0.8) 2 (1.5)
Patients with serious events, n (%) 18 (6.9) 0 4 (1.5) 0 1 (0.4) 1 (0.8)













Patients with event (all grades), n (%) 201 (77.3) 49 (37.7) 165 (63.5) 54 (41.5) 104 (40.0) 19 (14.6)
Median (range) number of adverse events per patient 1.00 (1–14) 1.00 (1–6) 1.00 (1–8) 1.00 (1–3) 1.00 (1−12) 1.00 (1–5)
Management, n (%)
Supportive treatment 117 (45.0) 15 (11.5) 11 (4.2) 0 28 (10.8) 3 (2.3)
Dose interruption 35 (13.5) 0 20 (7.7) 1 (0.8) 25 (9.6) 3 (2.3)
Dose reduction 10 (3.8) 0 15 (5.8) 1 (0.8) 0 0
Discontinuation 6 (2.3) 1 (0.8) 6 (2.3) 1 (0.8) 2 (0.8) 0
Outcome, n (%)b
Recovered/resolved 183 (91.0) 46 (93.9) 103 (62.4) 41 (75.9) 100 (96.2) 19 (100.0)
Recovered/resolved with sequelae 1 (0.5) 0 1 (0.6) 1 (1.9) 1 (1.0) 0
Recovering/resolving 2 (1.0) 1 (2.0) 13 (7.9) 3 (5.6) 1 (1.0) 0
Not recovered/resolved 15 (7.5) 2 (4.1) 48 (29.1) 9 (16.7) 2 (1.9) 0
Patients with grade ≥3 events, n (%) 2 (0.8) 0 10 (3.8) 2 (1.5) 1 (0.4) 1 (0.8)
Patients with serious events, n (%) 0 0 0 0 0 1 (0.8)
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Adverse events were monitored throughout study
treatment and for 30 days after discontinuation of study treatment.
a Grouped-term events.
b Percentages were calculated from the number of patients with that event.
Fig. 3.Olaparibdose reductions in SOLO1over time.Number of patients treated at the start of eachmonth. *‘Other Regimen’ includes 150mgqd, 150mgbid, 200mgqd, 250mgqd, 300mg
qd and 450 mg bid. †The category of ‘no dosing’ was assigned if the patient had dosing interrupted for the entire month window. bid, twice daily; qd, once daily.
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Table 3
Summary of AML cases.a






Reason for stopping olaparib Time to AML diagnosis
after stopping olaparib, days
Outcome
1 AML 52 BRCA1 mutation 436 Persistent neutropenia and anemia 173 Fatalb
2 AML 52 BRCA1 mutation 758 Completed 2 years' treatment 49 Fatalb
3 AML 64 BRCA2 mutation 519 Dyspnea, pyrexia, and URTI with subsequent disease
progressionc
52 Fatalb
AML, acute myeloid leukemia; URTI, upper respiratory tract infection.
a All three patients had previously received six cycles of carboplatin plus paclitaxel. Cytogenetic abnormalities detected in these patients were: deletion in chromosome 7 ormonosomy
7 (patient 1); deletion of the long arm of chromosome 5, with additional unidentifiedmaterial on the short arm of chromosome 15 and the long arm of chromosome 21 and loss of chro-
mosome 19 (patient 2); and loss of chromosome 7 (patient 3).
b In line with reporting standards for treatment-emergent adverse events, these cases of AML were not classified as adverse events resulting in death as death occurred >30 days after
discontinuation of olaparib.
c This patient discontinued olaparib on day 519 because of dyspnea, pyrexia and URTI. Radiologic disease progression was detected on day 570.
N. Colombo, K. Moore, G. Scambia et al. Gynecologic Oncology xxx (xxxx) xxxpneumonitis/ILD were reported in SOLO1. The clinical presentation of
pneumonitis/ILD is variable; interruption of maintenance olaparib is
recommended in patients with new or worsening respiratory symp-
toms or abnormal chest radiologic findings and prompt investigation
is warranted [12]. Olaparib should be discontinued if drug-induced
pneumonitis/ILD is confirmed; treatment with corticosteroids may be
indicated if pneumonitis/ILD is severe or progresses despite treatment
interruption [12,18].
Although similarities are evident in the tolerability profiles of the dif-
ferent PARP inhibitors, with olaparib, niraparib, rucaparib and veliparib
all associated with nausea, vomiting, fatigue/asthenia and anemia
[6,9,19–22], distinct differences are also observed. For example, the fre-
quency and severity of hematologic AEs differs between PARP inhibi-
tors. In SOLO1, grade ≥3 thrombocytopenia and neutropenia were
reported in 0.8% and 8.5% of olaparib patients, respectively. In a recent
phase III trial, grade ≥3 thrombocytopenia, decreased platelet count,
neutropenia and decreased neutrophil count were reported in 28.7%,
13.0%, 12.8% and 7.6% of patients, respectively, with newly diagnosed,
advanced ovarian cancer who received maintenance niraparib [21].
The increased risk of thrombocytopenia, particularly grade ≥3 thrombo-
cytopenia, necessitates weekly monitoring of blood counts for the first
month of maintenance niraparib [23,24], whereas only monthly moni-
toring is needed with olaparib [12].
In terms of non-hematologic AEs, the risk of hypertension, insomnia
or anxiety was not increased with olaparib versus placebo in SOLO1 [6].
However, these AEs have been reported with the PARP inhibitor
niraparib [19,21,23,24], with hypertension thought to be related to
off-target inhibition of dopamine, serotonin and norepinephrine trans-
porters [13,25]. Therewas also no increased risk of liver function test ab-
normalities with olaparib versus placebo in SOLO1 [6], whereas
increased levels of alanine and aspartate aminotransferase, mostly tran-
sient and self-limiting, have been reported with rucaparib in the re-
lapsed disease setting [20]. To date, pneumonitis/ILD has mainly been
reported, albeit rarely, with olaparib [6].
Strategies to mitigate for AEs with niraparib include starting at a
lower dosage of 200 mg once daily, rather than the recommended
starting dosage of 300mg once daily [23,24], in patientswith a low base-
line bodyweight or platelet count [26]. Grade ≥3 thrombocytopenia and
decreased platelet count were reported in 14.8% and 7.1% of patients, re-
spectively, who started maintenance niraparib at 200 mg once daily fol-
lowing a protocol amendment in a phase III trial [21]. SOLO1
demonstrates that maintenance olaparib can be dosed over the long
term in the first-line setting, with the majority of patients remaining
on the starting dose and schedule, which supports the recommendation
to start patients on an olaparib dosage of 300 mg twice daily [1,2].
5. Conclusions
Maintenance olaparib provided a substantial PFS benefit in patients
with newly diagnosed advanced ovarian cancer and a BRCAm in8
SOLO1. Maintenance olaparib had manageable toxicity, with no
new safety signals identified. The most commonly reported non-
hematologic and hematologic AEs usually occurred early. Of 162
patients still receiving olaparib at month 24, 64.2% were receiving the
recommended starting dose of olaparib 300 mg twice daily without re-
quiring a dose reduction, with 17% receiving a reduced olaparib dose of
250 mg twice daily.
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